Expressions Of β-tubulinⅢ And Stathmin In Advanced Non-Small Cell Lung Cancer And Its Relationship With Resistance To Docetaxel

Objective T To observe the change of (3-tubulin III and stathmin expression in advanced Non-small cell lung cancer and analysis its influence to docetaxel resistance and prognosis. Methods In this prospective study,selected ninety-five patients who diagnosed to be advanced or recurrent squamous cell lung cancer by histopathology, from October2007-August2012in the affiliated tumor hospital of Xinjiang Medical University.They were treated with cisplatin plus docetaxel chemotherapy, to evaluate the response rate (RR), time of tumor progression (TTP) and overall survival (OS).The expression of P-tubulin III and stathmin in tumor samples was detected by the immunohistochemical methods, to explore it as a predictor in advanced non-small cell lung cancer with docetaxel-containing chemotherapy. Results Study founded that P-tubulinⅢ and stathmin expression were not related to the clinical characteristics,or instance,the patients’ gender, age, smoking history(P>0.05);especially they had the higher expression in those patients with the bad PS score, advantaged stage and poor effect of chemotherapy (P<0.05).β-tubulin III high expression group with the response rate of chemotherapy24%(12/50) was significantly lower than the low expression group’s response rate42.2%(19/45)(P=0.049).There were statistically significant differences between Stathmin high and low expression group in response rate of chemotherapy, the former was22.6%(15/53),however,the latter was45.2%(19/42)(P=0.020). The analysis found that the group with both β-tubulinⅢ and stathmin low expression was61.9%response rate, the other group with their high expression was20.7%, two groups had significant difference(P=0.003).The TTP and MST were236days,387days, respectively in the group with both β-tubulinⅢ and stathmin low expression,significantly longer than the other group with their high expression of87days,148days respectively (P<0.001). With chi-square statistics tested β-tubulinⅢ no correlation with Stathmin express. Conclusion The high level expression of β-tubulinⅢ and stathmin in advanced NSCLC biopsies has indication with the poor sensitivity to docetaxel-containing chemotherapy,and poor prognosis in patients.